25.04.2016 • NewsCEODede WillamsJoseph C. Papa

Valeant on Verge of Hiring Perrigo’s CEO?

In its search for a new CEO to replace William J. Pearson, who has resigned amid several controversies, Canada-domiciled  embattled drugmaker Valeant is said to be finalizing a contract with Joseph C. Papa, chairman and CEO of Ireland-domiciled pharmaceutical producer Perrigo. Neither of the companies – both managed from the US – has been willing to comment on the speculation launched by The Wall Street Journal, which said the appointment could be announced as early as this week.

Valeant is under heavy scrutiny in the US Senate for price gouging. It also is being subjected to a US federal government audit of its accounting and pricing practices, as well more than one Securities and Exchange Commission (SEC) investigation.

Among other things, the SEC is looking into issues at Salix Pharmaceuticals, which was acquired by Valeant for $11 billion in 2015.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.